ArticleFrontiers in cardiovascular medicine2025
Serum albumin combined with high-density lipoprotein cholesterol as a novel marker to predict coronary heart disease: are their associations multiplicative or rateable?
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary heart disease (CHD) is a leading cause of death and disability worldwide. Albumin (ALB) and high-density lipoprotein cholesterol (HDL-c) possess potential clinical application values. However, the relationship between ALB*HDL-c (AHM) and CHD in the general population has not been studied yet. Therefore, this study aims to investigate the association between the AHM and CHD. Methods: We conducted a retrospective study using data from 2,568 patients with a diagnosis of CHD from Wuhan Fourth Hospital. Patients with one or more major coronary artery or branch vessel stenosis ≥ 50% were included in the CHD group, while patients without CHD were enrolled in the control group. Logistic regression analysis was performed to determine the influence of AHM on CHD. The receiver operating characteristic (ROC) curve was constructed to analyze the predictive value of AHM for CHD. Results: A total of 1,824 enrolled patients (71.0%) were diagnosed with CHD. The mean age was 64.56 ± 10.08 years. Notably, the CHD group had a substantially lower median AHM than that of the control group (36.94 vs. 52.63), with a statistically significant difference ( Conclusion: AHM was significantly linked to an elevated risk of CHD. The lower the AHM level, the greater the CHD occurrence rate. AHM is associated not only with the occurrence of CHD but also with the severity of coronary artery stenosis. This underscores the crucial value of AHM in the discrimination and management of CHD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.